Fziomed, Inc.

FzioMed – Pioneering Biomaterials to Improve Patients’ Lives

Pioneering biomaterials since 1996, Fziomed is a recognized global leader in postsurgical adhesion prevention focused on addressing an unmet clinical need in spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures. Fziomed develops, manufactures, and commercializes best-in-class surgical biomaterials used by clinicians to Preserve Surgical Excellence℠ and improve patient outcomes.

Brands: Oxiplex, Dynavisc, Oxiplex/AP, Oxiplex/IU

 Press Releases

• Fziomed Initiates Commercialization of Oxiplex Gel in the United States (Jun 10, 2026)

  Fziomed initiated US commercialization of Oxiplex, indicated for reducing postop leg pain and neurological symptoms following lumbar spine procedures.

• Fziomed Commemorates One Millionth Patient Treated With Its Dual-Polymer Ad (Jun 10, 2026)

  Company surpassed treating one million patients worldwide over the past 20+ years, including over 800,000 patients undergoing spine procedures.

• Fziomed Announces Clinical Results from Level I Study Evaluating Oxiplex Ab (Jun 10, 2026)

  Level I clinical study results demonstrates that Oxiplex improves pain and neurological outcomes when used as an adjuvant during lumbar spine surgery.